Business
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Adminis
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6KjMGJHKhj2fey6YfY3waA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252","width":300,"height":104}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 ","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 ","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 ","length":118,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":426,"olType":false},{"type":"text","content":"Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population1. The approval of a distinct biologic option for pediatric patients living with HS allows treatment to be tailored to the individual and establishes Cosentyx as a meaningful addition to the treatment landscape1-13.","length":570,"tagName":"p"},{"type":"text","content":"“Hidradenitis suppurativa (HS) often begins in adolescence and can cause irreversible scarring and disabilities,” said Alexa B. Kimball, MD, MPH, lead investigator of the SUNSHINE and SUNRISE clinical trials in adult HS patients, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, and Professor of Dermatology at Harvard Medical School. “The approval of Cosentyx represents&nb...